{"id":830850,"date":"2025-03-27T16:34:20","date_gmt":"2025-03-27T20:34:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-highlights\/"},"modified":"2025-03-27T16:34:20","modified_gmt":"2025-03-27T20:34:20","slug":"plus-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-highlights\/","title":{"rendered":"Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights"},"content":{"rendered":"

\nThe recent $15 million financing accelerates development of REYOBIQ\u2122 and launch of CNSide\u2122
\n<\/h2>\n
\n

HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc.<\/a> (Nasdaq:\u00a0PSTV<\/a>) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces\u00a0financial results for the fourth quarter and full year ended December 31, 2024, and provides an overview of recent and upcoming business highlights.<\/p>\n

\u201cOver the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in our two most advanced CNS cancer programs,\u201d said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. \u201cThe recently raised capital, coupled with existing grant support, enables us to progress both our therapeutic programs to key clinical and regulatory milestones as well as commercially launch our CNSide diagnostic platform. The year 2025 has the potential to be transformational at Plus as we anticipate transitioning to an operational revenue generating company with the launch of CNSide. We are highly appreciative of our investors, partners and other stakeholders for their continued commitment to Plus as we deliver on our objectives and drive value.\u201d<\/p>\n

\n Q4 2024 & RECENT HIGHLIGHTS AND MILESTONES<\/strong>\n <\/p>\n

\n
\n
\n Corporate<\/u>
\n <\/em>
\n <\/strong>\n <\/p>\n